Qiuyang Zhang1,2, Sen Liu1, Dongxia Ge1, David M Cunningham1, Feng Huang1,3, Lin Ma1,4, Thomas P Burris5, Zongbing You1,2,6,7,8. 1. Department of Structural & Cellular Biology, Tulane University, New Orleans, Louisiana. 2. Tulane Center for Aging, Tulane University, New Orleans, Louisiana. 3. Department of Clinical Medicine, The First Affiliated Hospital, Shaanxi University of Chinese Medicine, Xianyang, China. 4. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China. 5. Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, Missouri. 6. Department of Orthopaedic Surgery, Tulane University, New Orleans, Louisiana. 7. Tulane Cancer Center and Louisiana Cancer Research Consortium, Tulane University, New Orleans, Louisiana. 8. Tulane Center for Stem Cell Research and Regenerative Medicine, Tulane University, New Orleans, Louisiana.
Abstract
BACKGROUND: Chronic inflammation has been associated with the development and progression of human cancers including prostate cancer. The exact role of the inflammatory Th17-IL-17 pathway in prostate cancer remains unknown. In this study, we aimed to determine the importance of Th17 cells and IL-17 in a Pten-null prostate cancer mouse model. METHODS: The Pten-null mice were treated by Th17 inhibitor SR1001 or anti-mouse IL-17 monoclonal antibody from 6 weeks of age up to 12 weeks of age. For SR1001 treatment, the mice were injected intraperitoneally (i.p.) twice a day with vehicle or SR1001, which was dissolved in a dimethylsulfoxide (DMSO) solution. All mice were euthanized for necropsy at 12 weeks of age. For IL-17 antibody treatment, the mice were injected intravenously (i.v.) once every two weeks with control IgG or rat anti-mouse IL-17 monoclonal antibody, which was dissolved in PBS. The injection time points were at 6, 8, and 10 weeks old. All mice were analyzed for the prostate phenotypes at 12 weeks of age. RESULTS: We found that either SR1001 or anti-IL-17 antibody treatment decreased the formation of micro-invasive prostate cancer in Pten-null mice. The SR1001 or anti-IL-17 antibody treated mouse prostates had reduced proliferation, increased apoptosis, and reduced angiogenesis, as well as reduced inflammatory cell infiltration. By assessing the epithelial-to-mesenchymal transition (EMT) markers, we found that SR1001 or anti-IL-17 antibody treated prostate tissues had weaker EMT phenotype compared to the control treated prostates. CONCLUSIONS: These results demonstrated that Th17-IL-17 pathway plays a key role in prostate cancer progression in Pten-null mice. Targeting Th17-IL-17 pathway could prevent micro-invasive prostate cancer formation in mice. Prostate 77:888-899, 2017.
BACKGROUND:Chronic inflammation has been associated with the development and progression of humancancers including prostate cancer. The exact role of the inflammatory Th17-IL-17 pathway in prostate cancer remains unknown. In this study, we aimed to determine the importance of Th17 cells and IL-17 in a Pten-null prostate cancermouse model. METHODS: The Pten-null mice were treated by Th17 inhibitor SR1001 or anti-mouseIL-17 monoclonal antibody from 6 weeks of age up to 12 weeks of age. For SR1001 treatment, the mice were injected intraperitoneally (i.p.) twice a day with vehicle or SR1001, which was dissolved in a dimethylsulfoxide (DMSO) solution. All mice were euthanized for necropsy at 12 weeks of age. For IL-17 antibody treatment, the mice were injected intravenously (i.v.) once every two weeks with control IgG or rat anti-mouseIL-17 monoclonal antibody, which was dissolved in PBS. The injection time points were at 6, 8, and 10 weeks old. All mice were analyzed for the prostate phenotypes at 12 weeks of age. RESULTS: We found that either SR1001 or anti-IL-17 antibody treatment decreased the formation of micro-invasive prostate cancer in Pten-null mice. The SR1001 or anti-IL-17 antibody treated mouse prostates had reduced proliferation, increased apoptosis, and reduced angiogenesis, as well as reduced inflammatory cell infiltration. By assessing the epithelial-to-mesenchymal transition (EMT) markers, we found that SR1001 or anti-IL-17 antibody treated prostate tissues had weaker EMT phenotype compared to the control treated prostates. CONCLUSIONS: These results demonstrated that Th17-IL-17 pathway plays a key role in prostate cancer progression in Pten-null mice. Targeting Th17-IL-17 pathway could prevent micro-invasive prostate cancer formation in mice. Prostate 77:888-899, 2017.
Authors: Mia Shapiro; Bisweswar Nandi; Christine Pai; Mehmet K Samur; Dheeraj Pelluru; Mariateresa Fulciniti; Rao H Prabhala; Nikhil C Munshi; Jason S Gold Journal: Cancer Immunol Immunother Date: 2015-11-11 Impact factor: 6.968
Authors: Laura A Solt; Naresh Kumar; Philippe Nuhant; Yongjun Wang; Janelle L Lauer; Jin Liu; Monica A Istrate; Theodore M Kamenecka; William R Roush; Dušica Vidović; Stephan C Schürer; Jihong Xu; Gail Wagoner; Paul D Drew; Patrick R Griffin; Thomas P Burris Journal: Nature Date: 2011-04-17 Impact factor: 49.962
Authors: Sen Liu; Fengli Liu; Bing Zhang; Peng Yan; Brian G Rowan; Asim B Abdel-Mageed; Chad Steele; S Michal Jazwinski; Krzysztof Moroz; Elizabeth B Norton; Alun Wang; Leann Myers; Oliver Sartor; Qiuyang Zhang Journal: Prostate Date: 2020-05-01 Impact factor: 4.104
Authors: Daria Briukhovetska; Janina Dörr; Stefan Endres; Peter Libby; Charles A Dinarello; Sebastian Kobold Journal: Nat Rev Cancer Date: 2021-06-03 Impact factor: 69.800
Authors: Johann S de Bono; Christina Guo; Bora Gurel; Angelo M De Marzo; Karen S Sfanos; Ram S Mani; Jesús Gil; Charles G Drake; Andrea Alimonti Journal: Nat Rev Cancer Date: 2020-06-16 Impact factor: 60.716